Advertisement

Tumor Biology

, Volume 36, Issue 8, pp 6053–6062 | Cite as

Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer

  • Hafeza Akter
  • Min Park
  • Oh-Seung Kwon
  • Eun Joo Song
  • Won-Sang Park
  • Min-Jung Kang
Research Article

Abstract

Neurotensin (NT) is distributed throughout the brain and gastrointestinal tract. Although the relationship between NT and matrix metalloproteinase-9 (MMP-9) activity in gastric cancer has not been reported, the elevation of MMP-9 and NT is reported in the breast, lung, prostate, and gastric cancer. The aim of our study is to investigate the relationship between NT and MMP-9 activity and the underlying signaling mechanism in gastric cancer cell lines. Commercial ELISA kits were used for estimation of NT and MMP-9 expression, and fluorescence resonance energy transfer (FRET) assay was used for measurement of MMP-9 activity. Cell migration and invasion were determined by wound healing and transwell assay. The expression of signaling proteins was measured by Western blotting. Our study reveals a positive correlation between increased plasma NT and MMP-9 activity in both of patient’s serum and gastric cancer cell lines. A dose-dependent elevation of MMP-9 activity was observed by NT treatment in gastric cancer cells (MKN-1 and MKN-45) compared to untreated gastric cancer and normal epithelial cell (HFE-145). Moreover, NT-mediated migration and invasion were observed in gastric cancer cells unlike in normal cell. The signaling mechanism of NT in gastric cancer cells was confirmed in protein kinase C (PKC), extracellular-signal regulated kinase (ERK), and phosphatidylinositol 3-kinase (PI3K) pathway. In addition, pretreatment of gastric cancer cells with NTR1 inhibitor SR48692 was shown to significantly inhibit the NT-mediated MMP-9 activity, cell invasion, and migration. Our finding illustrated NTR1 could be a possible therapeutic target for gastric cancer.

Keywords

Neurotensin NTR1 ELISA MMP-9 Invasion ERK 

Notes

Acknowledgments

This study was supported by the Creative Fusion Research Program through the Creative Allied Project funded by Korea Research Council of Science and Technology (CAP-12-1-KIST) and Korea Institute of Science and Technology (KIST) Institutional Program (project no. 2E25360).

Conflicts of interest

None

Supplementary material

13277_2015_3282_MOESM1_ESM.pptx (399 kb)
Supplementary Fig. 1 (PPTX 399 kb)

References

  1. 1.
    Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010;127:2918–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Mirvish SS. Gastric-cancer and salivary nitrate and nitrite. Nature. 1985;315:461–2.CrossRefPubMedGoogle Scholar
  3. 3.
    Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713–39.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lo SS, Wu CW, Hsieh MC, Kuo HS, Lui WY, Peng FK. Relationship between age and clinical characteristics of patients with gastric cancer. J Gastroenterol Hepatol. 1996;11:511–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5:121–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Lam KWK, Lo SCL. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin Appl. 2008;2:219–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011;78:120–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Kikuchi R, Abe Y, Iijima K, Koike T, Ara N, Uno K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med. 2011;223:35–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006;27:2445–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Reubi JC, Waser B, Schmassmann A, Laissue JA. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int J Cancer. 1999;81:376–86.CrossRefPubMedGoogle Scholar
  11. 11.
    Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H, et al. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer. 2008;123:1816–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Kalafatakis K, Triantafyllou K. Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul Peptides. 2011;170:7–17.CrossRefGoogle Scholar
  13. 13.
    Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, Ahmed-Zaid SM, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010;16:4401–10.CrossRefPubMedGoogle Scholar
  15. 15.
    Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate. 1997;31:183–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66:6243–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Tatsuta M, Iishi H, Baba M, Taniguchi H. Promotion by neurotensin of gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1989;49:843–6.PubMedGoogle Scholar
  18. 18.
    Wood JG, Hoang HD, Bussjaeger LJ, Solomon TE. Neurotensin stimulates growth of small-intestine in rats. Am J Physiol. 1988;255:G813–7.PubMedGoogle Scholar
  19. 19.
    Hasegawa K, Kar S, Carr BI. Stimulation of hepatocyte DNA-synthesis by neurotensin. J Cell Physiol. 1994;158:215–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Sillem M, Prifti S, Koumouridis A, Runnebaum B. Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines. Eur J Gynaecol Oncol. 1999;20:367–70.PubMedGoogle Scholar
  21. 21.
    Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH, Lee SY. Anti-metastatic effect of cantharidin in a549 human lung cancer cells. Arch Pharm Res. 2013;36:479–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012;50:12–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Li L, Tan J, Zhang Y, Han N, Di X, Xiao T, et al. DLK1 promotes lung cancer cell invasion through upregulation of MMP9 expression depending on Notch signaling. PLoS One. 2014;9:e91509.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zheng SQ, Chang YH, Hodges KB, Sun Y, Ma XB, Xueyi NON, et al. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 2010;30:713–8.PubMedGoogle Scholar
  25. 25.
    Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000;6:2726–34.PubMedGoogle Scholar
  26. 26.
    Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, et al. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Investig. 2011;40:447–64.CrossRefGoogle Scholar
  27. 27.
    Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, et al. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013;190:4420–30.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res. 2010;316:24–37.CrossRefPubMedGoogle Scholar
  29. 29.
    Liao A, Wang W, Sun D, Jiang Y, Tian S, Li J, Yang X, Shi R. Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.Google Scholar
  30. 30.
    Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang YY, Sein TT, et al. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis. 2001;18:423–8.CrossRefGoogle Scholar
  31. 31.
    Itoh S, Hamada E, Kamoshida G, Takeshita K, Oku T, Tsuji T. Staphylococcal superantigen-like protein 5 inhibits matrix metalloproteinase 9 from human neutrophils. Infect Immun. 2010;78:3298–305.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yao GY, Zhou JL, Lai MD, Chen XQ, Chen PH. Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases. World J Gastroenterol. 2003;9:858–61.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    FernandezFernandez L, Tejero E, Tieso A, Rabadan L, Munoz M, Santos I. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Int Surg. 1996;81:400–2.Google Scholar
  34. 34.
    Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74:413–7.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.PubMedGoogle Scholar
  36. 36.
    Chinni SR, Sivalogan S, Dong Z, Trindade JC, Deng XY, Bonfil RD, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate. 2006;66:32–48.CrossRefPubMedGoogle Scholar
  37. 37.
    Lee CW, Lin CC, Lin WN, Liang KC, Luo SF, Wu CB, et al. TNF-alpha induces MMP-9 expression via activation of SRC/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappab/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L799–812.CrossRefPubMedGoogle Scholar
  38. 38.
    Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J : Off Publ Fed Am Soc Exp Biol. 2004;18:1123–5.CrossRefGoogle Scholar
  39. 39.
    Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 2006;25:7009–18.CrossRefPubMedGoogle Scholar
  40. 40.
    Guha S, Lunn JA, Santiskulvong C, Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2003;63:2379–87.PubMedGoogle Scholar
  41. 41.
    di Florio A, Sancho V, Moreno P, Delle Fave G, Jensen RT. Gastrointestinal hormones stimulate growth of foregut neuroendocrine tumors by transactivating the EGF receptor. BBA Mol Cell Res. 2013;1833:573–82.Google Scholar
  42. 42.
    Zachary I, Rozengurt E. Modulation of the epidermal growth-factor receptor by mitogenic ligands: effects of bombesin and role of protein-kinase C. Cancer Surv. 1985;4:729–65.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Hafeza Akter
    • 1
    • 3
  • Min Park
    • 1
  • Oh-Seung Kwon
    • 2
    • 3
  • Eun Joo Song
    • 1
    • 3
  • Won-Sang Park
    • 4
  • Min-Jung Kang
    • 1
    • 3
  1. 1.Molecular Recognition Research CenterKorea Institute of Science and TechnologySeoulSouth Korea
  2. 2.Doping Control CenterKorea Institute of Science and TechnologySeoulSouth Korea
  3. 3.Department of Biological ChemistryKorea University of Science and TechnologyDaejeonSouth Korea
  4. 4.Department of Pathology, College of MedicineThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations